Characterization of Inhibitor-Bound α-Synuclein Dimer: Role of α-Synuclein N-Terminal Region in Dimerization and Inhibitor Binding

Journal of Molecular Biology

Volumn 395, Issue 3, 2010, Pages 445-456

  Yamaguchi, Yoshiki ^a,b   Masuda, Masami ^c,d   Sasakawa, Hiroaki ^a,e   Nonaka, Takashi ^c   Hanashima, Shinya ^b   Hisanaga, Shin ichi ^d   Kato, Koichi ^a,e,f   Hasegawa, Masato ^c  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b Advanced Science Institute   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d TOKYO METROPOLITAN UNIVERSITY   (Japan)

^e INSTITUTE FOR MOLECULAR SCIENCE   (Japan)

^f OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

dimer; dopamine; NMR; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DIMER; DOPAMINE; EXIFONE; GOSSYPETIN; METHIONINE; MONOMER; PROTEINASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOBLOTTING; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION STATE; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 73549109861     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.10.068     Document Type: Article

References (22)

1. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294 (2001) 1346-1349
2. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., et al. Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 272 (2005) 3661-3672
3. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., et al. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45 (2006) 6085-6094
4. Porat Y., Abramowitz A., and Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67 (2006) 27-37
5. Feng B.Y., Toyama B.H., Wille H., Colby D.W., Collins S.R., May B.C., et al. Small-molecule aggregates inhibit amyloid polymerization. Nat. Chem. Biol. 4 (2008) 197-199
6. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M. Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
7. Herrera F.E., Chesi A., Paleologou K.E., Schmid A., Munoz A., Vendruscolo M., et al. Inhibition of α-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE e3394 (2008) 3
8. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15 (2008) 558-566
9. Moussa C.E., Mahmoodian F., Tomita Y., and Sidhu A. Dopamine differentially induces aggregation of A53T mutant and wild type α-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem. Biophys. Res. Commun. 365 (2008) 833-839
10. Rao J.N., Dua V., and Ulmer T.S. Characterization of α-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry 47 (2008) 4651-4656
11. Hong D.P., Fink A.L., and Uversky V.N. Structural characteristics of α-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383 (2008) 214-223
12. Masuda M., Hasegawa M., Nonaka T., Oikawa T., Yonetani M., Yamaguchi Y., et al. Inhibition of α-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett. 583 (2009) 787-791
13. Sasakawa H., Sakata E., Yamaguchi Y., Masuda M., Mori T., Kurimoto E., et al. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of α-synuclein. Biochem. Biophys. Res. Commun. 363 (2007) 795-799
14. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., and Fink A.L. Methionine oxidation inhibits fibrillation of human α-synuclein in vitro. FEBS Lett. 517 (2002) 239-244
15. Paz M.A., Gallop P.M., Torrelio B.M., and Fluckiger R. The amplified detection of free and bound methoxatin (PQQ) with nitroblue tetrazolium redox reactions: insights into the PQQ-locus. Biochem. Biophys. Res. Commun. 154 (1988) 1330-1337
16. Ingrosso D., Fowler A.V., Bleibaum J., and Clarke S. Specificity of endoproteinase Asp-N (Pseudomonas fragi): cleavage at glutamyl residues in two proteins. Biochem. Biophys. Res. Commun. 162 (1989) 1528-1534
17. Tetaz T., Morrison J.R., Andreou J., and Fidge N.H. Relaxed specificity of endoproteinase Asp-N: this enzyme cleaves at peptide bonds N-terminal to glutamate as well as aspartate and cysteic acid residues. Biochem. Int. 22 (1990) 561-566
18. Stadtman E.R., Van Remmen H., Richardson A., Wehr N.B., and Levine R.L. Methionine oxidation and aging. Biochim. Biophys. Acta 1703 (2005) 135-140
19. Rospigliosi C.C., McClendon S., Schmid A.W., Ramlall T.F., Barre P., Lashuel H.A., and Eliezer D. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in α-synuclein. J. Mol. Biol. 388 (2009) 1022-1032
20. Jakes R., Spillantini M.G., and Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345 (1994) 27-32
21. Masuda M., Dohmae N., Nonaka T., Oikawa T., Hisanaga S., Goedert M., and Hasegawa M. Cysteine misincorporation in bacterially expressed human α-synuclein. FEBS Lett. 580 (2006) 1775-1779
22. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., and Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6 (1995) 277-293